Stock comparison
Side-by-side financials for BGLC and EXAS. Compare market value, revenue, profit, margins, filings, and source pages in one place.
Quick answer
EXAS is larger
Market cap data is available for the leading company in this comparison.
Market value leader
EXAS
Latest market capitalization comparison.
Revenue leader
EXAS
BGLC: $7.42M vs EXAS: $3.25B.
Profit leader
BGLC
BGLC: -$2.98M vs EXAS: -$207.95M.
Margin leader
EXAS
BGLC: -40.2% vs EXAS: -6.4% net margin.
| Metric | BGLC | EXAS |
|---|---|---|
| Market cap | - | $20.03 B |
| US-listed rank | - | #625 |
| Revenue (latest FY) | $7.42M | $3.25B |
| Net income (latest FY) | -$2.98M | -$207.95M |
| Net margin | -40.2% | -6.4% |
| P/E (trailing FY) | - | - |
| SEC filings | 140 | 1,834 |
Jump from this comparison into the underlying pages for market value, annual fundamentals, and company filing history.
Market cap uses refreshed market data. Revenue, net income, margins, and trailing fiscal-year P/E use annual company facts from filings. If a metric is missing, the source data did not have a clean recent annual value for that company.
In their latest fiscal years, BioNexus Gene Lab Corp reported $7.42M in revenue while EXACT SCIENCES CORP reported $3.25B.
Full pages: BioNexus Gene Lab Corp and EXACT SCIENCES CORP, or browse the full rankings.